文献速递MDS 与骨髓增殖性肿瘤白血病

体内消融NF-κB级联效应分子减轻骨髓增殖性肿瘤疾病负荷

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2024-01-01

研究通过条件性敲除Rela、Myd88及扰动miR-146a,在Jak2V617F和MPLW515L驱动的小鼠模型及患者来源异种移植(PDX)模型中系统消融NF-κB信号效应分子,发现RELA敲低可减轻白血病植入与骨髓纤维化并延长生存,而miR-146a扰动则加重疾病。药理学抑制IRAK4(CA-4948)在MPN中抑制疾病负荷和炎症细胞因子且未在非疾病模型诱导毒性。

要点

  • 条件性敲除Rela减轻Jak2V617F驱动的真性红细胞增多症和MPLW515L驱动的骨髓纤维化疾病标志。
  • PDX模型中RELA敲除减少白血病植入和骨髓纤维化并延长生存。
  • IRAK4抑制剂CA-4948在MPN中抑制疾病负荷和炎症细胞因子,非疾病模型未诱导毒性。

核心结论

  • MPN中存在可被新兴治疗手段利用的NF-κB级联脆弱性。

研究设计与样本

  • 研究使用一系列原代样本以及同基因和患者来源异种移植(PDX)小鼠模型。
  • 采用条件性敲除和扰动NF-κB信号效应分子以系统识别核心依赖。

主要发现

  • 条件性敲除Rela分别减弱Jak2V617F驱动的真性红细胞增多症和MPLW515L驱动的骨髓纤维化疾病标志的发生。
  • PDX中RELA敲除减少白血病植入和骨髓纤维化,同时延长生存。
  • 敲除上游效应分子Myd88也减轻疾病负荷;相反,扰动负调节因子miR-146a microRNA诱导更早致死并加重疾病。
  • 扰动NF-κB效应分子进一步改变造血多能祖细胞的丰度和分布。
  • 用抑制剂CA-4948药理学靶向白细胞介素-1受体相关激酶4(IRAK4)在MPN中抑制疾病负荷和炎症细胞因子,且在非疾病模型中未诱导毒性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperactivation of the NF-κB cascade propagates oncogenic signaling and proinflammation, which together augments disease burden in myeloproliferative neoplasms (MPNs). Here, we systematically ablate NF-κB signaling effectors to identify core dependencies using a series of primary samples and syngeneic and patient-derived xenograft (PDX) mouse models. Conditional knockout of Rela attenuated Jak2V617F- and MPLW515L-driven onset of polycythemia vera and myelofibrosis disease hallmarks, respectively. In PDXs, RELA knockout diminished leukemic engraftment and bone marrow fibrosis while extending survival. Knockout of upstream effector Myd88 also alleviated disease burden; conversely, perturbation of negative regulator miR-146a microRNA induced earlier lethality and exacerbated disease. Perturbation of NF-κB effectors further skewed the abundance and distribution of hematopoietic multipotent progenitors. Finally, pharmacological targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) with inhibitor CA-4948 suppressed disease burden and inflammatory cytokines specifically in MPN without inducing toxicity in nondiseased models. These findings highlight vulnerabilities in MPN that are exploitable with emerging therapeutic approaches.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Laranjeira ABA, Kong T, Snyder SC, et al. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. 2024. PMID: 38457657. doi:10.1182/blood.2023022804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。